Design of an Aseptic Process Simulation

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-09-02-2004
Volume 28
Issue 9

The authors suggest a design strategy for an aseptic process simulation that focuses on the basic repeating unit of the process, establishing alert and action criteria for the unit itself, and using worst-case simulations to establish routine operational parameters for the manufacturing process.

External Link - article-122725.pdf

Articles in this issue
Excel file and formula for Determining Probability of Passing the USP Content Uniformity Test
In the Spotlight-September 2004
Promoting Quality in Drug Manufacturing
Automation in a Digital, Webbed, and Wireless Age
September 2004
Design of an Aseptic Process Simulation
Use of the Bergum Method and MS Excel to Determine the Probability of Passing the USP Content Uniformity Test
Characterization of the Performance of Bin Blenders-Part 3 of 3: Cohesive Powders
Early Development Still Driving CRO Performance
Particulate-Free Pallets
Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Ross Announces PFA-Coated Ribbon Blender to Be Offered for Sensitive Applications

Patrick Lavery
March 6th 2025
Article

The company said this blender supports applications for which either stainless steel or carbon steel may not be suitable.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Novartis Treatment for C3G Gets Positive Opinion from EMA

Patrick Lavery
March 4th 2025
Article

CHMP gave its opinion and a recommendation for marketing authorization to Fabhalta (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Pushing Tech Boundaries

Mike Hennessy Jr.
March 3rd 2025
Article

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia

Patrick Lavery
March 3rd 2025
Article

Jaypirca (pirtobrutinib) has received a conditional marketing authorization from EMA for mantle cell lymphoma. The drug was approved in the United States in 2023 for several indications.